Strata Q4 rev +10% to $9.6M; net loss $4.5M; adj. EBITDA improves to $2.2M in 2024

STRATA Skin Sciences, Inc.

Q4 2024 revenue $9.6M, up 10% from $8.7M; net loss $4.5M (EPS -$1.18 vs -$1.09).
Full-year 2024 revenue $33.6M (flat); net loss $10.1M (EPS -$2.65).
Gross margin improved to 60.1% in Q4 (480 bps YoY); non-GAAP adj. EBITDA $2.2M vs $1.0M.
Domestic XTRAC units reduced to 864; avg rev per device up 6% to $5,906.
International Q4 sales $4.1M (+41% YoY); cash $8.6M at year end.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.